About Cytel
Cytel is a company based in Cambridge (United States) founded in 1987 by Cyrus Mehta and Nitin Patel was acquired by Nordic Capital in December 2020. Cytel has raised $2 million across 8 funding rounds from investors including Merck, HHS and New Mountain Capital. Cytel has completed 5 acquisitions, including MTEK Sciences, Purple Squirrel and SDS Life Science. Cytel offers products and services including Trial Design Software, Axio Data Monitoring, and LiveSLR Software. Cytel operates in a competitive market with competitors including Charles River Laboratories, DNAnexus, LabCorp, Precision Medicine Group and Frontage Laboratories, among others.
- Headquarter Cambridge, United States
- Founders Cyrus Mehta, Nitin Patel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cytel Statistical Software & Services Pr Ivate Limited
- Date of Incorporation 03 Apr, 2001
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$17.87 M (USD)13.09as on Mar 31, 2023
-
Net Profit
$2.87 M (USD)37.2as on Mar 31, 2023
-
EBITDA
$3.19 M (USD)15.37as on Mar 31, 2023
-
Total Equity Funding
$2 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
Merck
& 5 more
-
Employee Count
Not available
-
Investments & Acquisitions
MTEK Sciences
& 4 more
-
Acquired by
Nordic Capital
(Dec 21, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cytel
Cytel offers a comprehensive portfolio of products and services, including Trial Design Software, Axio Data Monitoring, and LiveSLR Software.
Enables simulation and optimization of clinical trial protocols.
Facilitates monitoring and analysis of clinical trial data.
Supports systematic literature reviews for research insights.
People of Cytel
Unlock access to complete
Senior Team
82 people
Leadership Team
75 people
Principal Team
57 people
Data Analysis and Operations Team
35 people
Statistical Team
25 people
Software Development Team
16 people
Finance and Accounting
15 people
Product Management Team
8 people
Unlock access to complete
Funding Insights of Cytel
Cytel has successfully raised a total of $2M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cytel
Cytel has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, HHS and New Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
New Mountain Capital manages investments in private equity, credit, and net lease strategies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cytel
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cytel
Cytel has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include MTEK Sciences, Purple Squirrel and SDS Life Science.
Investment portfolio details for Cytel
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of project management and quality assurance services for medical devices manufacturers
|
Locked | Locked | 2020 | Locked | |
|
Software is developed for clinical study design and analysis.
|
Locked | Locked | 2017 | Locked | |
|
Provider of market access services to biopharma sector
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Cytel
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cytel
Detailed financials for Cytel
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytel Comparisons
Peer comparison for Cytel
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cytel
Cytel operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, DNAnexus, LabCorp, Precision Medicine Group and Frontage Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of drug discovery and preclinical development services
|
|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Provider of laboratory tests for physicians
|
|
| Locked | Locked | Locked |
Provider of clinical research, development, and commercialization services for life sciences
|
|
| Locked | Locked | Locked |
Early drug development services are provided for pharma firms.
|
Detailed competitors of Cytel
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytel
Complete news archive for Cytel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytel
Cytel was founded in 1987 and raised its 1st funding round 7 years after it was founded.
Cytel is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jovan Willford is the current CEO of Cytel.
Cytel is a funded company, having raised a total of $2M across 8 funding rounds to date.
Annual revenue of Cytel is $17.87M as on Mar 31, 2023.
Cytel was founded in 1987 and is headquartered in Cambridge, United States. Statistical solutions and data analytics are offered for the life sciences sector, focusing on clinical trial design, analysis, and real-world evidence generation. Software tools and services are supplied to support drug development processes, including regulatory submissions. Operations emphasize insights for pharmaceutical and biotech applications across global markets.
Cytel's top competitors include DNAnexus, LabCorp and Charles River Laboratories.
Cytel offers Trial Design Software, Axio Data Monitoring, and LiveSLR Software.
Cytel has made 5 acquisitions, including MTEK Sciences, Purple Squirrel, and SDS Life Science.
Cytel has 6 investors. Key investors include Merck, HHS, New Mountain Capital, NIH SBIR/STTR, and Nordic Capital.